The Latest Cardiac and Vascular News
DANVERS, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), the leader in heart recovery, announces its initiatives at the 30th Transcatheter Cardiovascular Therapeutics (TCT) conference will highlight the recently expanded FDA indications for high-risk PCI and cardiogenic shock. Initiatives will also highlight Protected PCI’s ability to allow for […]
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the company has randomized its first patient in the CARILLON Pivotal Trial. The CARILLON Trial is evaluating the Carillon® Mitral Contour System®for the treatment of functional […]
OAKLAND, Calif.–(BUSINESS WIRE)–LUMEDX Corporation, a provider of wholly integrated cardiovascular data intelligence and imaging solutions, announced today that it is working with Duke Health to implement a comprehensive cardiovascular information system (CVIS) for Duke’s non-invasive cardiac labs. The implementation marks the third phase of a larger Duke-LUMEDX CVIS project, which […]
RESEARCH TRIANGLE PARK, N.C. & TORONTO–(BUSINESS WIRE)–Analytics 4 Life, a digital health company dedicated to improving existing diagnostic pathways, today announced that clinical data will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 scientific symposium. Dr. Thomas Stuckey, a primary investigator on the Company’s Coronary Artery Disease Learning and […]
LAVAL, Quebec, Sept. 18, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today provided a clinical and market update. Jan D’Alvise, president […]
WESTMINSTER, Colo., Sept. 18, 2018 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA). The request is part of the […]
MARLBOROUGH, Mass., Sept. 17, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE :BSX ) today announced key data that will be presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in San Diego, on September 21 – September 25. Data from the head-to-head IMPERIAL trial evaluating the ELUVIA™ […]
BE’ER SHEVA, Israel, and HARTFORD, Conn., Sept. 18, 2018 /PRNewswire/ — DiA Imaging Analysis Ltd. (DiA), a provider of artificial intelligence (AI)-powered ultrasound analysis tools, announced today that its LVivo EF cardiac decision-support software is now available for purchase for GE’s new Vscan Extend™ handheld, pocket-sized ultrasound. This collaboration is an outgrowth of work between DiA […]
DUBLIN – September 18, 2018 – Medtronic plc (NYSE:MDT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a single-arm study to evaluate the CoreValve Evolut(TM)TAVR system in patients with bicuspid aortic valves who are at low risk of surgical mortality. […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the first successful implantation of the VITARIA® System in a patient enrolled in the Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure With Reduced Ejection Fraction (ANTHEM-HFrEF) Pivotal Study. The study is an international, multi-center, randomized trial to evaluate the VITARIA System for the […]
